JOSÉ LUIS
CABRIADA NUÑO
Investigador hasta 2022
Hospital de Cruces
Barakaldo, EspañaPublicaciones en colaboración con investigadores/as de Hospital de Cruces (24)
2024
-
Transmural cross-sectional findings and bowel damage assessment in preclinical Crohn’s disease: a case-control study
International Journal of Colorectal Disease, Vol. 39, Núm. 1
2023
-
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU
American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046
2022
-
Management and Long-term Outcomes of Crohn's Disease Complicated with Enterocutaneous Fistula: ECUFIT Study from GETECCU
Journal of Crohn's & colitis, Vol. 16, Núm. 7, pp. 1049-1058
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
2020
-
Characteristics and Prognosis of Patients With Inflammatory Bowel Disease During the SARS-CoV-2 Pandemic in the Basque Country (Spain)
Gastroenterology, Vol. 159, Núm. 2, pp. 781-783
-
Early microscopic findings in preclinical inflammatory bowel disease
Digestive and Liver Disease, Vol. 52, Núm. 12, pp. 1467-1472
2019
-
Immunosuppression for inflammatory bowel disease does not influence Epstein–Barr viral load in the short-term
Gastroenterologia y Hepatologia, Vol. 42, Núm. 9, pp. 542-547
-
The relationship between inflammatory bowel disease and Parkinson’s disease: true or fiction?
Scandinavian Journal of Gastroenterology
2018
-
Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors
Digestive and Liver Disease, Vol. 50, Núm. 8, pp. 812-819
-
Characteristics and Progression of Preclinical Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, Vol. 16, Núm. 9, pp. 1459-1466
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279
2017
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Granulocyte-Monocyte Apheresis as an Adjuvant Therapy to Anti-Tumor Necrosis Factor Drugs for Ulcerative Colitis
Therapeutic Apheresis and Dialysis, Vol. 21, Núm. 1, pp. 26-30
2016
-
Previous exposure to biologics and C-reactive protein are associated with the response to tacrolimus in inflammatory bowel disease
Revista Espanola de Enfermedades Digestivas, Vol. 108, Núm. 9, pp. 550-557
2014
-
Disease severity in familial cases of IBD
Journal of Crohn's and Colitis, Vol. 8, Núm. 3, pp. 234-239
-
Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database
Journal of Crohn's and Colitis, Vol. 8, Núm. 7, pp. 654-661
-
Risk of colectomy in patients with ulcerative colitis under thiopurine treatment
Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293
2013
-
Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome
Journal of Crohn's and Colitis, Vol. 7, Núm. 9, pp. 717-722
-
Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era
Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760